Eli Lilly announced Thursday that tirzepatide (trade name: Mounjaro), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been officially marketed in China covering two indications: type 2 diabetes and weight loss.

Mounjaro is currently available in China in four sizes, including 2.5 mg:0.5 ml, 5 mg:0.5 ml, 7.5 mg:0.5 ml, and 10 mg:0.5 ml.

It is the world's first and currently only once-weekly GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management.

The weight-loss version of tirzepatide, with revenues of $3.018 billion in the first three quarters of 2024, is in the top tier of the global GLP-1 track with Novo Nordisk's GLP-1 drug semaglutide (trade name: Wegovy).

Previous media reports have mentioned that a number of Chinese e-commerce platforms already have diagnosis and pickup services for tirzepatide, with prices varying across the platforms' various merchants.